MA43724A - Molécules bispécifiques de cellules t activées par une protéase - Google Patents

Molécules bispécifiques de cellules t activées par une protéase

Info

Publication number
MA43724A
MA43724A MA043724A MA43724A MA43724A MA 43724 A MA43724 A MA 43724A MA 043724 A MA043724 A MA 043724A MA 43724 A MA43724 A MA 43724A MA 43724 A MA43724 A MA 43724A
Authority
MA
Morocco
Prior art keywords
cells
bispecific molecules
protease activated
protease
activated
Prior art date
Application number
MA043724A
Other languages
English (en)
Other versions
MA43724B1 (fr
Inventor
Peter Bruenker
Rebecca Croasdale-Wood
Martina Geiger
Christian Klein
Jigar Patel
Juergen Michael Schanzer
Kay-Gunnar Stubenrauch
Eric Sullivan
Pablo Umana
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA43724A publication Critical patent/MA43724A/fr
Publication of MA43724B1 publication Critical patent/MA43724B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
MA43724A 2016-03-22 2017-03-20 Molécules bispécifiques de cellules t activées par une protéase MA43724B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16161740 2016-03-22
PCT/EP2017/056556 WO2017162587A1 (fr) 2016-03-22 2017-03-20 Molécules bispécifiques de cellules t activées par une protéase

Publications (2)

Publication Number Publication Date
MA43724A true MA43724A (fr) 2018-11-28
MA43724B1 MA43724B1 (fr) 2023-06-28

Family

ID=55646332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43724A MA43724B1 (fr) 2016-03-22 2017-03-20 Molécules bispécifiques de cellules t activées par une protéase

Country Status (14)

Country Link
EP (1) EP3433280B1 (fr)
KR (1) KR102444614B1 (fr)
CN (1) CN108884170A (fr)
AR (2) AR107946A1 (fr)
AU (1) AU2017237376B2 (fr)
BR (1) BR112018016281A2 (fr)
CA (1) CA3012422A1 (fr)
CO (1) CO2018007556A2 (fr)
CR (1) CR20180453A (fr)
MA (1) MA43724B1 (fr)
PE (1) PE20181891A1 (fr)
PT (1) PT3433280T (fr)
SG (1) SG11201808085WA (fr)
WO (1) WO2017162587A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986254A1 (fr) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion
EP3297672B1 (fr) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Protéines trispécifiques de liaison et méthodes d'utilisation
JPWO2018097308A1 (ja) 2016-11-28 2019-10-17 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
EP3546574A4 (fr) 2016-11-28 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Domaine de liaison à l'antigène et polypeptide comprenant une section de transport
CN110637033A (zh) * 2017-02-22 2019-12-31 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
JP7066837B2 (ja) 2017-10-13 2022-05-13 ハープーン セラピューティクス,インク. B細胞成熟抗原結合タンパク質
JP7438106B2 (ja) 2017-10-14 2024-02-26 シートムエックス セラピューティクス,インコーポレイテッド 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法
MX2020005220A (es) * 2017-11-28 2020-08-24 Chugai Pharmaceutical Co Ltd Polipeptido que incluye dominio de union al antigeno y seccion de transporte.
US20210206845A1 (en) * 2017-11-28 2021-07-08 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
US20210115106A1 (en) * 2017-12-07 2021-04-22 Janux Therapeutics, Inc. Modified t cell receptors
US12060424B2 (en) 2017-12-21 2024-08-13 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
AR115360A1 (es) * 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
WO2019222275A2 (fr) * 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions et procédés de reprogrammation de tcr utilisant des protéines de fusion inductibles
SG11202011330PA (en) * 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
WO2019230867A1 (fr) 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprenant un domaine de liaison à l'aggrécane et une fraction de transport
CA3102823A1 (fr) 2018-06-22 2019-12-26 Cugene Inc. Medicaments bioactivables a base de cytokine et procedes d'utilisations associes
AU2019310855A1 (en) * 2018-07-24 2021-03-11 Crage Medical Co., Limited Method for treating tumor using immune effector cell
WO2020069028A1 (fr) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Protéines de liaison à dll3 et méthodes d'utilisation
EP4151722A1 (fr) * 2018-11-16 2023-03-22 Celgene Corporation Processus amélioré de fabrication de cellules t
EP3954707A1 (fr) 2018-12-21 2022-02-16 Zhejiang Shimai Pharmaceutical Co., Ltd. Anticorps bispécifiques clivables par la protéase et leurs utilisations associées
SG11202109884WA (en) * 2019-03-29 2021-10-28 Green Cross Corp Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
MX2021014433A (es) * 2019-06-05 2022-03-11 Chugai Pharmaceutical Co Ltd Molecula de union a sitio de escision de anticuerpo.
WO2020252264A1 (fr) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation
KR20220041851A (ko) * 2019-07-19 2022-04-01 우시 바이올로직스 아일랜드 리미티드 접합을 위한 폴리펩티드 복합체 및 이의 용도
AU2021254279A1 (en) 2020-04-09 2022-11-10 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
US20230312753A1 (en) 2020-05-04 2023-10-05 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
MX2022015890A (es) * 2020-06-19 2023-01-24 Hoffmann La Roche Anticuerpos biespecificos para linfocitos t activados por proteasa.
WO2022170619A1 (fr) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anticorps anti-cd3 et leurs méthodes d'utilisation
AU2022367525A1 (en) * 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
MX2024004563A (es) * 2021-10-15 2024-04-30 Cytomx Therapeutics Inc Complejo polipeptidico activable.
AR128876A1 (es) * 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
WO2023192973A1 (fr) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Molécules multispécifiques activables et leurs méthodes d'utilisation
WO2023220647A1 (fr) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Proprotéines de molécules de liaison multispécifiques et leurs utilisations
WO2023222580A1 (fr) 2022-05-16 2023-11-23 Byondis B.V. Nouveaux anticorps masqués
CN116724057A (zh) * 2022-11-28 2023-09-08 浙江时迈药业有限公司 蛋白酶可切割的重组双特异性抗体和组合物及其用途
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156905B (it) 1977-04-18 1987-02-04 Hitachi Metals Ltd Articolo di ornamento atto ad essere fissato mediante un magnete permanente
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック, インコーポレイテッド ヒト化抗TGF−β抗体
EP2360186B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
AU2006211037B2 (en) 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
ES2429340T3 (es) * 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014004549A2 (fr) * 2012-06-27 2014-01-03 Amgen Inc. Protéines de liaison anti-mésothéline
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
AU2014236769B2 (en) * 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
CN113248615A (zh) * 2013-07-05 2021-08-13 根马布股份公司 人源化或嵌合cd3抗体
EP3024851B1 (fr) * 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Anticorps multispécifiques, anticorps activables multispécifiques et leurs méthodes d'utilisation
WO2015048272A1 (fr) * 2013-09-25 2015-04-02 Amgen Inc. Anticorps v-c-fc-v-c
CN107108738A (zh) * 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
EP2982692A1 (fr) * 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
KR20170083095A (ko) * 2014-11-11 2017-07-17 아뮤닉스 오퍼레이팅 인코포레이티드 표적화된 xten 접합체 조성물 및 이의 제조 방법
RS60615B1 (sr) * 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
WO2016146894A1 (fr) * 2015-03-17 2016-09-22 Tilt Biotherapeutics Oy Adénovirus oncolytiques codant pour des anticorps bi-spécifiques et méthodes et utilisations associées

Also Published As

Publication number Publication date
PE20181891A1 (es) 2018-12-11
EP3433280B1 (fr) 2023-04-19
KR102444614B1 (ko) 2022-09-21
AU2017237376B2 (en) 2024-03-07
BR112018016281A2 (pt) 2019-01-02
CR20180453A (es) 2018-12-05
CO2018007556A2 (es) 2018-07-31
AU2017237376A1 (en) 2018-08-02
AR107946A1 (es) 2018-06-28
PT3433280T (pt) 2023-06-15
WO2017162587A1 (fr) 2017-09-28
MA43724B1 (fr) 2023-06-28
SG11201808085WA (en) 2018-10-30
AR120543A2 (es) 2022-02-23
CN108884170A (zh) 2018-11-23
KR20180128407A (ko) 2018-12-03
EP3433280A1 (fr) 2019-01-30
CA3012422A1 (fr) 2017-09-28

Similar Documents

Publication Publication Date Title
MA43724A (fr) Molécules bispécifiques de cellules t activées par une protéase
DK3608337T3 (da) Bispecifikke T-celleaktiverende antigenbindende molekyler
DK3331876T3 (da) Modulators of ror-gamma
DK3172227T3 (da) Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
MA44474A (fr) Nouveaux inhibiteurs de la ferroportine
EA201691974A1 (ru) Антитела против ox40 и способы их применения
DK3119884T3 (da) Serinproteaser af bacillus-arter
DK3131928T4 (da) Trifunktionel antigen-bindende molekyle
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
MA55746A (fr) Molécules multispécifiques ciblant cll-1
CL2014001826S1 (es) Auto de carrera
DK3377206T3 (da) Medieblandekammer
DK3242685T3 (da) Cxcr4-bindende molekyler
DK3283210T3 (da) Fremgangsmåde
DK3132009T3 (da) Fremgangsmåde
BR112016019822A2 (pt) Determinação enzimática de hba1c
IT201600129491A1 (it) Avantreno di motoveicolo rollante con blocco di rollio
FR3023067B1 (fr) Cellules tandem multifils
IT201600129489A1 (it) Avantreno di motoveicolo rollante con blocco di rollio
IT201600130313A1 (it) Struttura portante di veicolo
DK2897382T3 (da) Forbedring af binaural kilde
DK3204037T3 (da) Sammensætninger og kits til enzymatisk debridering og fremgangsmåder til anvendelse deraf
IT201600129497A1 (it) Avantreno di motoveicolo rollante con blocco di rollio
FI20155387A (fi) Sterolien tuottaminen
DK3606953T3 (da) Fgfr3-bindende molekyler